Mon. Jun 5th, 2023
  • Evaxion created a genetic adjuvant technologies that boosts the immune responses of viral, bacterial and cancer vaccines
  • Preclinically validated for each DNA and mRNA vaccines, and prepared for clinical testing  
  • Anticipated significant industry possible for DNA and mRNA vaccines against cancer, viral and bacterial ailments

COPENHAGEN, Denmark, May well 25, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology enterprise specializing in the discovery and improvement of AI-powered immunotherapies, nowadays unveils the technologies behind its novel, proprietary genetic adjuvant created to boost the effectiveness of DNA and mRNA vaccines for infectious ailments and cancer. 

Newest information from the adjuvant system had been presented at Evaxion’s reside stream R&ampD Day, May well 25, 2023. 

“We are excited to present this novel genetic adjuvant technologies to the worldwide scientific neighborhood. It boosts Evaxion´s personal DNA technologies and has the possible to strengthen the impact of practically any vaccine. We foresee a excellent industry possible in that this technologies seems to be hugely helpful in each DNA and mRNA primarily based vaccines against cancer as effectively as infectious ailments,” stated Per Norlén, CEO at Evaxion

Evaxion´s novel genetic adjuvant carries the code for CCL19, a molecule identified to attract immune cells, notably antigen presenting cells, and can be encoded into either DNA or mRNA vaccines with the aim of boosting the immune response. 

Newest information show that the genetic adjuvant technologies boosts the antitumor impact in preclinical tumor models, and induces neutralizing antibodies and T-cell responses against each viral and bacterial antigens: 

  • Delivery of DNA or mRNA cancer neoantigen vaccines induced powerful neoantigen-particular T-cell responses and comprehensive antitumor responses
  • Delivery of a COVID-19 T-cell epitope DNA vaccine resulted in a powerful and particular T-cell response and protected against a lethal dose of the virus (90% survival)
  • Delivery of a Neisseria Gonorrhoeae antigen DNA vaccine induced higher antibody titers and particular T-cell responses towards the bacterial antigens
  • Per Norlén continues, “By encoding the immune-stimulating molecule CCL19 into either DNA or mRNA vaccines, we have demonstrated substantial enhancement of the vaccines effectiveness. We think that this advancement holds immense possible for vaccine improvement, as it boosts each B cell and T cell immune responses, generating it applicable to a wide variety of vaccines. Constructing on the encouraging preclinical final results, the subsequent step is to validate the technologies in individuals.” 

    Evaxion aims to bring the genetic adjuvant technologies into clinical trials later this year as element of the customized cancer immunotherapy system EVX-03.  

    Please check out the Investors section of Evaxion’s web-site to access a replay of the R&ampD Day presentations. 

    About Evaxion

    Evaxion Biotech A/S is a pioneering enterprise building AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune technique to find out and create novel immunotherapies for cancer, bacterial ailments, and viral infections. Evaxion has a broad pipeline of candidates, like 3 customized cancer immunotherapies. It is positioned in Hørsholm, Denmark, with 50 staff listed on the Nasdaq New York stock exchange. For extra data, please check out www.evaxion-biotech.com.

    Forward-seeking statement 
    This announcement includes forward-seeking statements inside the which means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of related which means determine forward-seeking statements. Actual final results may perhaps differ materially from these indicated by such forward-seeking statements as a outcome of numerous elements, like, but not restricted to, dangers connected to: our monetary situation and need to have for extra capital our improvement perform price and good results of our solution improvement activities and preclinical and clinical trials commercializing any authorized pharmaceutical solution created utilizing our AI platform technologies, like the price and degree of industry acceptance of our solution candidates our dependence on third parties like for conduct of clinical testing and solution manufacture our inability to enter into partnerships government regulation protection of our intellectual home rights employee matters and managing development our ADSs and ordinary shares, the influence of international financial, political, legal, compliance, social and organization elements, like inflation, and the effects on our organization from the worldwide COVID-19 pandemic and the ongoing conflict in the area surrounding Ukraine and Russia and other uncertainties affecting our organization operations and monetary situation. For a additional discussion of these dangers, please refer to the threat elements integrated in our most current Annual Report on Type 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are accessible at www.sec.gov. We do not assume any obligation to update any forward-seeking statements except as necessary by law.

    By Editor

    Leave a Reply